Ideaya Biosciences Inc (IDYA) Stock Down -0.63%: Is It a Good Investment?

A share price of Ideaya Biosciences Inc [IDYA] is currently trading at $42.30, down -0.63%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IDYA shares have gain 0.36% over the last week, with a monthly amount drifted -2.94%, and not seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

On 5, April 2024, IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on March 28, 2024, the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 70,000 shares of the Company’s common stock to two newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals’ entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

From an analyst’s perspective:

Ideaya Biosciences Inc [NASDAQ: IDYA] stock has seen the most recent analyst activity on March 08, 2024, when BTIG Research initiated its Buy rating and assigned the stock a price target of $55. Previously, SVB Securities started tracking the stock with Outperform rating on August 08, 2023, and set its price target to $33. On May 24, 2023, Goldman initiated with a Buy rating and assigned a price target of $32 on the stock. Stifel upgraded its rating to a Buy and increased its price target to $24 on April 24, 2023. Berenberg initiated its recommendation with a Buy and recommended $26 as its price target on March 23, 2023. RBC Capital Mkts started tracking with a Outperform rating for this stock on February 28, 2023, and assigned it a price target of $25. In a note dated December 28, 2022, CapitalOne initiated an Overweight rating and provided a target price of $29 on this stock.

Ideaya Biosciences Inc experienced fluctuations in its stock price throughout the past year between $13.29 and $47.74. Currently, Wall Street analysts expect the stock to reach $24.75 within the next 12 months. Ideaya Biosciences Inc [NASDAQ: IDYA] shares were valued at $42.30 at the most recent close of the market. An investor can expect a potential drop of -41.49% based on the average IDYA price forecast.

Analyzing the IDYA fundamentals

Trailing Twelve Months sales for Ideaya Biosciences Inc [NASDAQ:IDYA] were 23.39M which represents -2.46% decline. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -5.75%, Pretax Profit Margin comes in at -4.83%, and Net Profit Margin reading is -4.68%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.22 and Total Capital is -0.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 41.45 points at the first support level, and at 40.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 42.78, and for the 2nd resistance point, it is at 43.26.

Ideaya Biosciences Inc [IDYA] reported earnings per share of -$0.52 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.47/share, meaning a difference of -$0.05 and a surprise factor of -10.60%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.46 per share as compared to estimates of -$0.49 per share, a difference of $0.03 representing a surprise of 6.10%.

Ratios To Look Out For

To put it in perspective, the Current Ratio for Ideaya Biosciences Inc [NASDAQ:IDYA] is 19.65. Further, the Quick Ratio stands at 19.65, while the Cash Ratio is 5.79. Considering the valuation of this stock, the price to sales ratio is 134.84, the price to book ratio is 4.43.

Transactions by insiders

Recent insider trading involved Hata Yujiro S, President and CEO, that happened on Feb 09 ’24 when 23557.0 shares were sold., Ruiz Briseno Andres completed a deal on Feb 09 ’24 to sell 2000.0 shares. Meanwhile, President and CEO Hata Yujiro S sold 75815.0 shares on Feb 08 ’24.

Related Posts